Actuate Therapeutics Prices $11 Million Public Offering
The Fort Worth-based firm announced pricing for a new public offering of shares and warrants expected to close this week.
Updated on Oct. 27, 2026 in Public Companies
Live Poll
Is now a good time for individual investors to participate in public biotech stock offerings?
Actuate Therapeutics has priced an $11 million underwritten public offering of common stock and warrants. The offering is expected to close on October 28, 2026.
Why it matters
The company intends to use the net proceeds from this offering to support working capital needs and fund general corporate purposes. This financial move allows the firm to secure necessary capital to continue its ongoing business operations.
The offering includes 30,985,900 shares of common stock and 15,492,950 warrants at a price of $0.71 per set, with warrants exercisable at $0.45 per share. Gross proceeds are anticipated to reach approximately $11.0 million.
The players
Actuate Therapeutics
This is a biopharmaceutical company headquartered in Fort Worth, Texas.
Newbridge Securities Corporation
This firm is a financial services company acting as the sole book-running manager for the offering.
The details
Newbridge Securities Corporation serves as the sole book-running manager for the transaction, which was filed under SEC File No. 333-299332. The offering also grants the underwriter a 45-day option to purchase additional shares and warrants to cover potential over-allotments.
Timeline
October 27, 2026: Actuate Therapeutics announced the pricing of the offering.
October 28, 2026: The offering is expected to close.
45 days from October 27, 2026: The underwriter's option to purchase additional securities expires.
Five years from issuance: The warrants expire.
Market Landscape
This capital raise highlights the ongoing trend of biotechnology companies leveraging public markets to stabilize liquidity. It follows established SEC compliance protocols that dictate how smaller firms raise funds to remain competitive against larger industry incumbents.
The offering allows Actuate Therapeutics to bolster its financial position, which may influence its long-term project viability for shareholders. Customers or partners should monitor the firm's progress as it deploys these funds into its general operations.
The takeaway
This transaction provides Actuate Therapeutics with significant immediate capital to support its corporate initiatives. Investors should note that the exercise of the included warrants could provide additional future funding for the company.
Further reading
For more information on the current fiscal state of local firms, visit Public Companies.
More information
Review the full details of this filing on the SEC website for prospectus.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Is now a good time for individual investors to participate in public biotech stock offerings?
